International Psoriasis Council

Advancing Knowledge. Improving Care.

Jeffrey

Cohen

,

MD, MPH

Assistant Professor of Dermatology
Yale School of Medicine
New Haven
,
Connecticut
,
United States
Councilor Since: June 14, 2024
IPC Councilor
Dr. Jeffrey M. Cohen, MD, is the director of the Psoriasis Treatment Program at the Yale University School of Medicine, where he also serves as Assistant Professor of Dermatology and Biomedical Informatics and Data Science and the Director of Safety for the Department of Dermatology. Dr. Cohen’s clinical practice is focused on inflammatory skin diseases such as psoriasis. Dr. Cohen’s research interest is dermatoepidemiology, and he uses large databases to understand associations between skin conditions and other medical conditions and characterize dermatology treatment patterns. He is also actively engaged in translational research to improve our understanding of the immunology of inflammatory skin diseases. He has published over 150 papers in peer-reviewed journals and serves on the Editorial Board of the Journal of the American Academy of Dermatology (JAAD). In addition to being an IPC Councilor, Dr. Cohen is on the Medical Board of the National Psoriasis Foundation (NPF). Dr. Cohen is a graduate of Harvard Medical School, completed an internship in the Department of Medicine at Beth Israel Deaconess Medical Center, and did his dermatology residency in The Ronald O. Perelman Department of Dermatology at the New York University School of Medicine.
Last Updated:
07/09/2024

Areas of Interest

Therapeutic development in the area of biologics and other systemic agents for psoriasis; epidemiology of inflammatory skin diseases like psoriasis; translational research to better understand the immunological underpinnings of psoriasis

Languages Spoken

English

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026